TABLE 2.
CAB/FLU
|
|||||
---|---|---|---|---|---|
Voriconazole
|
CAB
|
FLU
|
|||
IV | Oral | IV | IV | Oral | |
Dose (mg/kg) | 3–6 | 200–400 | 1 | 400 | 400 |
Weighted average cost per day ($) | 411–709 | 93 | 71 | 73 | 22 |
Mean duration of initial drug therapy (days) | |||||
Completed initial therapy | |||||
Toxicity | 12.8 | 7.3 | 6.5 | 6.8 | 7.3 |
No toxicity | 11.3 | 8.5 | 5.3 | 7.4 | 6.7 |
Discontinued initial therapy | |||||
Due to toxicity | 7.4 | 1.2 | 3.2 | 1.4 | 0.8 |
Due to lack of efficacy or other | 11.5 | 4.0 | 4.7 | 5.0 | 3.0 |
Died during active treatment | 8.0 | 0.4 | 4.5 | 4.2 | 0.2 |
The base-case analysis assumes that any unused drug remaining after administration was discarded. Because conventional amphotericin B (CAB) is indicated for several conditions other than candidemia, a sensitivity analysis was performed, in which any unused CAB remaining after administration was recycled for future use. Because the base-case analysis assumes any unused CAB remaining after administration was discarded, the choice between using a CAB dose of 0.7 mg/kg or 1.0 mg/kg is of negligible importance. Under both dosing scenarios, the weighted average number of vials required for each patient is two vials per day. FLU Fluconazole; IV Intravenous